Table 1.
Innate immune cells impacted by Chinese medicine compounds.
| Immune cells | Chinese medicine compounds | Signaling pathway/Cytokines | Specific main effects | Cancer types | Ref |
|---|---|---|---|---|---|
| Macrophages | Modified Si-Jun-Zi Decoction | ↑GM-CSF, IFN-γ, IL-1α, IL-3, | ↑Macrophages | Colorectal cancer | (21) |
| Haimufang decoction | ↑TNF-α, IL-1β, IL-12 p70, IL-6 | ↑Macrophages activity and M1 | Lewis lung cancer | (22) | |
| Compound kushen injection | ↑NF-κB and p38 MAPK signaling pathway | ↑Macrophages activity and M1 | Hepatocellular carcinoma | (23) | |
| Yu-Ping-Feng | ↑STAT1 signaling pathway, IL-1β, IL-12, iNOS | ↑The number and polarization of M1 | Orthotopic lung cancer | (24) | |
| XIAOPI formula | ↓TAMs/CXCL1 signaling pathway | ↓Proliferation and polarization of M2 | Breast cancer | (25) | |
| Dahuang Zhechong Pills | ↓CCL2, CCR2, F4/80, TGF-β1, FN | ↓Function and polarization of M2 | Colorectal cancer | (27) | |
| Jianpi Yangzheng | ↑IL-1β, IL-12, TNF-α; ↓Arg-1, Fizzl, Yml | ↑The conversion of TAMs from M2 to M1 | Gastric cancer | (28) | |
| DCs | Yu-Ping-Feng | ↑IL-12 | ↑The maturation and percentage of DCs | Hepatocellular carcinoma | (12) |
| Yangyin Wenyang | ↑MAPK, NF-κB signaling pathways | ↑The number and maturation of DCs | Non-small cell lung cancer | (29) | |
| Compound kushen injection | ↑IL-12 | ↑The killing activity of DC-cCSC FCs | Colorectal cancer | (30) | |
| NK cells | Yu-Ping-Feng | ↓TGF-β, Indoleamine 2,3-dioxygenase, IL-10; ↑IL-12 | ↑NK cell tumor infiltration and NK cell cytotoxicity | Lewis lung cancer | (31) |
| Jinfukang | ↑CX3CL1, TNF-α, Fas/FasL signaling pathway | ↑The recruitment and cytotoxicity of NK cells | Lewis lung cancer | (32) | |
| Tien-Hsien liquid | ↑IFN-γ, IL-2, TNF-α | ↑The number and tumor-killing activities of NK cells | Colorectal cancer | (33) | |
| ACNO | ↑IL-2, IL-12, INF-γ | ↑The number and cytotoxicity of NK cells | Colorectal cancer | (34) | |
| MDSCs | XIAOPI formula | ↓TAMs/CXCL1 signaling pathway | ↓The differentiation of HSPC into MDSCs | Breast cancer | (25) |
| YHD | ↓TGF-β and p-STAT3 | ↓The function of MDSCs | (35) | ||
| Yu-Ping-Feng | ↓Arg-1, iNOS, STAT3 ↓p-Akt, p-MEK, p-ERK, p-STAT3 | ↓The proportions of MDSCs subsets; ↑Apoptosis of MDSCs | Lewis lung cancer | (36) | |
| Jianpi Huayu Decoction | ↓IL-10, TGF - β | ↑The differentiation of MDSCs | Hepatocellular carcinoma | (37) | |
| Baoyuan Jiedu decoction | ↓TGF-β/CCL9 signaling pathway | ↓The content of G-MDSC and M-MDSC | Breast cancer | (38) | |
| Ze-Qi-Tang | ↓STAT3/S100A9/Bcl-2/caspase-3 signaling pathway | ↑The elimination of MDSCs (especially G-MDSCs) | Orthotopic lung cancer | (39) | |
| Shuangshen granules | ↓mTOR/S6K1/Myc signaling pathway | ↓The differentiation of BMCs into MDSCs | Lewis lung cancer | (40) |
↑, Up-regulated or enhanced; ↓, Down-regulated or inhibited.